Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss per share

Loss per share

6 Months Ended

Jun. 30, 2022

Note 4 — Loss per share

The following table reconciles the numerator and denominator in the basic and diluted loss per share computation (in thousands):


	Three months ended				Six months ended
	June 30,				June 30,
	2022		2021		2022		2021
Numerator for basic and diluted loss per share
Net loss attributable to ordinary shareholders	$	(44,520)	$	(39,068)	$	(94,785)	$	(76,831)
Net loss attributable to ordinary shareholders used for basic and diluted loss per share	$	(44,520)	$	(39,068)	$	(94,785)	$	(76,831)


	Three months ended		Six months ended
	June 30,		June 30,
	2022	2021	2022	2021
Denominator for basic and diluted loss per share - Weighted average shares outstanding	962,794,072	934,228,095	951,474,546	932,667,125

The dilutive effect of 150,711,054 and 113,659,553 stock options outstanding as of June 30, 2022 and 2021, respectively have been excluded from the diluted loss per share calculation for the three and six months ended June 30, 2022 and 2021 because they would have an antidilutive effect on the loss per share for the period.